Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Silverback Therapeutics, Inc. (SBTX) is Being Sued for Misleading Investors

November 12, 2021 GMT

SAN DIEGO--(BUSINESS WIRE)--Nov 12, 2021--

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased Silverback Therapeutics, Inc. (NASDAQ: SBTX) securities pursuant to the Company’s initial public offering (“IPO”) or between December 3, 2020 and September 10, 2020. The complaint alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934. Silverback is a clinical-stage biopharmaceutical company that develops tissue-targeted therapeutics. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial.


If you suffered a loss due to Silverback Therapeutics, Inc.’s misconduct, click here.

Silverback Therapeutics, Inc. (SBTX) Misled Investors Regarding its Lead Product Candidate

According to the complaint, Silverback began trading on the NASDAQ on December 3, 2020, issuing 11.5 million shares of common stock at $21.00 per share. The Offering Documents, however, were negligently prepared and contained material misleading statements. Specifically, the Offering Documents failed to disclose that SBT6050 was less effective than the Company had represented to investors and the Company had therefore overstated SBT6050′s commercial and/or clinical prospects.

On September 13, 2021, Silverback issued a press release “announc[ing] that interim data from the dose-escalation portion of its Phase 1/1b clinical trial evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors” showed that “while there was a manageable safety profile for the Company’s experimental therapy, SBT6050 yielded only one partial response among 14 HER2-positive solid tumors.” On this news, Silverback’s stock price fell $4.54 per share or over 23%, to close at $14.90 per share on September 13, 2021.

If you purchased shares of Silverback Therapeutics, Inc. (SBTX) securities pursuant to the Company’s IPO or between December 3, 2020 and September 10, 2020, you have until January 4, 2022, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:


Aaron Dumas
(800) 350-6003
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Silverback Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on

CONTACT: Aaron Dumas

Robbins LLP

(800) 350-6003




Copyright Business Wire 2021.

PUB: 11/12/2021 11:15 AM/DISC: 11/12/2021 11:15 AM